# Sheng-yong Yang

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 62 papers | 1,644 citations | 21 h-index | 39 g-index |
| 63 ext. papers | 1,936 ext. citations | 5.6 avg, IF | 5.06 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 62 | Pharmacophore modeling and applications in drug discovery: challenges and recent advances. *Drug Discovery Today*, **2010**, 15, 444-50 | 8.8 | 488 |
| 61 | A facile large-scale microwave synthesis of highly fluorescent carbon dots from benzenediol isomers. *Journal of Materials Chemistry C*, **2014**, 2, 5028-5035 | 7.1 | 63 |
| 60 | Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking. *Journal of Chemical Information and Modeling*, **2011**, 51, 1364-75 | 6.1 | 58 |
| 59 | NMR-filtered virtual screening leads to non-metal chelating metallo-β-lactamase inhibitors. *Chemical Science*, **2017**, 8, 928-937 | 9.4 | 52 |
| 58 | Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. *Cell Death and Disease*, **2017**, 8, e2534 | 9.8 | 49 |
| 57 | Tet Enzymes Regulate Telomere Maintenance and Chromosomal Stability of Mouse ESCs. *Cell Reports*, **2016**, 15, 1809-21 | 10.6 | 49 |
| 56 | Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant [illegible] | 8.3 | 48 |
| 55 | An integrated scheme for feature selection and parameter setting in the support vector machine modeling and its application to the prediction of pharmacokinetic properties of drugs. *Artificial Intelligence in Medicine*, **2009**, 46, 155-63 | 7.4 | 42 |
| 54 | Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. *Journal of Medicinal Chemistry*, **2012**, 55, 10685-99 | 8.3 | 37 |
| 53 | Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents. *Journal of Medicinal Chemistry*, **2015**, 58, 2764-78 | 8.3 | 33 |
| 52 | Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer. *Journal of Medicinal Chemistry*, **2015**, 58, 3957-74 | 8.3 | 32 |
| 51 | Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 1581-8 | 2.9 | 32 |
| 50 | Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling. *Theranostics*, **2018**, 8, 4995-5011 | 12.1 | 32 |
| 49 | Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo. *Journal of Medicinal Chemistry*, **2012**, 55, 3852-66 | 8.3 | 29 |
| 48 | A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 407-18 | 6.1 | 25 |
| 47 | Synthesis and biological evaluation of novel (E)-N∀(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 4552-4557 | 2.9 | 24 |
| 46 | Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers. *Journal of Medicinal Chemistry*, **2017**, 60, 6337-6352 | 8.3 | 24 |

| | | | |
|---|---|---|---|
| 45 | Drug Discovery against Psoriasis: Identification of a New Potent FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor, 1-(4-((1H-Pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea, That Showed Potent Activity in a Psoriatic Animal Model. *Journal of Medicinal Chemistry*, **2016**, 59, 8293-305 | 8.3 | 23 |
| 44 | Identification of new p300 histone acetyltransferase inhibitors from natural products by a customized virtual screening method. *RSC Advances*, **2016**, 6, 61137-61140 | 3.7 | 23 |
| 43 | IFPTarget: A Customized Virtual Target Identification Method Based on Protein-Ligand Interaction Fingerprinting Analyses. *Journal of Chemical Information and Modeling*, **2017**, 57, 1640-1651 | 6.1 | 23 |
| 42 | SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML. *Scientific Reports*, **2015**, 5, 15646 | 4.9 | 23 |
| 41 | Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. *Journal of Medicinal Chemistry*, **2018**, 61, 11398-11414 | 8.3 | 21 |
| 40 | LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors. *European Journal of Medicinal Chemistry*, **2015**, 93, 523-38 | 6.8 | 19 |
| 39 | Improved activity of lipase immobilized in microemulsion-based organogels for (, )-ketoprofen ester resolution: Long-term stability and reusability. *Biotechnology Reports (Amsterdam, Netherlands)*, **2015**, 7, 1-8 | 5.3 | 18 |
| 38 | Engineering P450 Peroxygenase to Catalyze Highly Enantioselective Epoxidation of cis-β-Methylstyrenes. *Chemistry - A European Journal*, **2016**, 22, 10969-75 | 4.8 | 18 |
| 37 | Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations. *Chemical Biology and Drug Design*, **2017**, 89, 585-598 | 2.9 | 18 |
| 36 | Structural insights into drug development strategy targeting EGFR T790M/C797S. *Oncotarget*, **2018**, 9, 13652-13665 | 3.3 | 18 |
| 35 | Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer. *Molecular Cancer Therapeutics*, **2016**, 15, 366-78 | 6.1 | 17 |
| 34 | Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 3231-3237 | 2.9 | 16 |
| 33 | Virtual screening in small molecule discovery for epigenetic targets. *Methods*, **2015**, 71, 158-66 | 4.6 | 16 |
| 32 | Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 2284-8 | 2.9 | 16 |
| 31 | Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. *European Journal of Medicinal Chemistry*, **2019**, 181, 111535 | 6.8 | 16 |
| 30 | A prediction model of drug-induced ototoxicity developed by an optimal support vector machine (SVM) method. *Computers in Biology and Medicine*, **2014**, 51, 122-7 | 7 | 16 |
| 29 | Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer. *Cancer Letters*, **2019**, 458, 76-85 | 9.9 | 15 |
| 28 | Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3. *ChemMedChem*, **2010**, 5, 513-6 | 3.7 | 15 |

| | | | |
|---|---|---|---|
| 27 | From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer. *Journal of Medicinal Chemistry*, **2016**, 59, 9788-9805 | 8.3 | 14 |
| 26 | Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer. *Journal of Medicinal Chemistry*, **2018**, 61, 881-904 | 8.3 | 13 |
| 25 | Enhanced turnover rate and enantioselectivity in the asymmetric epoxidation of styrene by new T213G mutants of CYP 119. *RSC Advances*, **2014**, 4, 27526-27531 | 3.7 | 13 |
| 24 | Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 3201-3204 | 2.9 | 12 |
| 23 | Discovery and structure-activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 5449-53 | 2.9 | 12 |
| 22 | Synthesis and evaluation of styrylpyran fluorophores for noninvasive detection of cerebral β-amyloid deposits. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 827-34 | 3.4 | 12 |
| 21 | Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 4534-8 | 2.9 | 11 |
| 20 | CapsCarcino: A novel sparse data deep learning tool for predicting carcinogens. *Food and Chemical Toxicology*, **2020**, 135, 110921 | 4.7 | 11 |
| 19 | Discovery of a Prenylated Flavonol Derivative as a Pin1 Inhibitor to Suppress Hepatocellular Carcinoma by Modulating MicroRNA Biogenesis. *Chemistry - an Asian Journal*, **2019**, 14, 130-134 | 4.5 | 11 |
| 18 | PRMT1 promotes neuroblastoma cell survival through ATF5. *Oncogenesis*, **2020**, 9, 50 | 6.6 | 10 |
| 17 | Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis. *European Journal of Medicinal Chemistry*, **2019**, 181, 111541 | 6.8 | 10 |
| 16 | TS-Chemscore, a Target-Specific Scoring Function, Significantly Improves the Performance of Scoring in Virtual Screening. *Chemical Biology and Drug Design*, **2015**, 86, 1-8 | 2.9 | 10 |
| 15 | 5-Methoxyquinoline Derivatives as a New Class of EZH2 Inhibitors. *Molecules*, **2015**, 20, 7620-36 | 4.8 | 9 |
| 14 | Facile Synthesis of 6-Aryl-3-cyanopyridine-2-(1H)-thiones from Aryl Ketones. *Synthetic Communications*, **2012**, 42, 1521-1531 | 1.7 | 9 |
| 13 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. *European Journal of Medicinal Chemistry*, **2018**, 143, 1148-1164 | 6.8 | 8 |
| 12 | A pyrane based fluorescence probe for noninvasive prediction of cerebral β-amyloid fibrils. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 4472-6 | 2.9 | 7 |
| 11 | Free energy profiles for monomer capture in Grubbs- and SHOP-type olefin polymerization catalysts: a constraint ab initio molecular dynamics study. *Journal of Computational Chemistry*, **2007**, 28, 513-8 | 3.5 | 5 |
| 10 | Design, Synthesis, and Biological Evaluation of 1-Benzyl-1H-pyrazole Derivatives as Receptor Interacting Protein 1 Kinase Inhibitors. *Chemical Biology and Drug Design*, **2016**, 87, 569-74 | 2.9 | 5 |

| | | | |
|---|---|---|---|
| 9 | YL4073 is a potent autophagy-stimulating antitumor agent in an in vivo model of Lewis lung carcinoma. *Oncology Reports*, **2016**, 35, 2081-8 | 3.5 | 4 |
| 8 | Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127215 | 2.9 | 3 |
| 7 | Discovery of 12O-A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor. *Molecules*, **2020**, 25, | 4.8 | 2 |
| 6 | Discovery of thieno[2,3-d]pyrimidin-4(3H)-one derivatives as a new class of ROCK inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 126966 | 2.9 | 1 |
| 5 | A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models. *Oncotarget*, **2017**, 8, 111495-111507 | 3.3 | 1 |
| 4 | Whether proton transition to the triphosphate tail of ATP occurs at protein kinase environment: A Car-Parrinello ab initio molecular dynamics study. *International Journal of Quantum Chemistry*, **2008** , 108, 1239-1245 | 2.1 | 1 |
| 3 | DCLK1 autoinhibition and activation in tumorigenesis.. *Innovation(China)*, **2022**, 3, 100191 | 17.8 | 1 |
| 2 | Pharmacophore-Based De Novo Design **2013**, 201-214 | | |
| 1 | Discovery of small molecule FLT3 inhibitors that are able to overcome drug-resistant mutations. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127532 | 2.9 | |